Aliases & Classifications for Vaginal Disease

MalaCards integrated aliases for Vaginal Disease:

Name: Vaginal Disease 12 15
Vaginal Diseases 42 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:121
MeSH 43 D014623
NCIt 49 C26910
SNOMED-CT 67 25658005
UMLS 71 C0042251

Summaries for Vaginal Disease

MedlinePlus : 42 Vaginal problems are some of the most common reasons women go to the doctor. They may have symptoms such as Itching Burning Pain Abnormal bleeding Discharge One common problem is vaginitis, an inflammation of the vagina. Other problems that affect the vagina include sexually transmitted diseases, vaginal cancer, and vulvar cancer. Treatment of vaginal problems depends on the cause.

MalaCards based summary : Vaginal Disease, also known as vaginal diseases, is related to vaginal discharge and vaginitis, and has symptoms including pelvic pain and leukorrhea. An important gene associated with Vaginal Disease is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Etonogestrel and Norethindrone have been mentioned in the context of this disorder. Affiliated tissues include vagina, bone and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A female reproductive system disease that is located in the vagina.

Wikipedia : 74 A vaginal disease is a pathological condition that affects part or all of the... more...

Related Diseases for Vaginal Disease

Diseases related to Vaginal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 630)
# Related Disease Score Top Affiliating Genes
1 vaginal discharge 32.4 SLPI IL6 CXCL8 CD4
2 vaginitis 31.6 TNF TLR4 TLR2 SLPI IL6 IL1B
3 genital herpes 30.1 TLR2 IL10 CD8A CD4 CCR6
4 trichomoniasis 29.9 TNF SLPI IL6 CXCL8 CD4 CCR5
5 herpes simplex 29.9 TNF TLR9 TLR3 TLR2 CD8A
6 cervical cancer 29.3 TNF TLR9 TLR4 IL6 IL10 CXCL8
7 leukoplakia of vagina 11.0
8 mycobacterium chelonae 10.7 TLR2 CXCL8
9 external pathological resorption 10.7 TNF IL6
10 cork-handlers' disease 10.7 CD8A CD4
11 subcutaneous mycosis 10.7 TLR7 CLEC7A CCR6
12 cutaneous candidiasis 10.7 TLR3 CLEC7A CCR6
13 spongiotic dermatitis 10.7 CD8A CD4 CCR6
14 syphilitic meningitis 10.7 CD8A CD4
15 mycobacterium marinum 10.6 TLR2 CXCL8
16 scorpion envenomation 10.6 TNF IL6
17 dermatophytosis 10.6 CLEC7A CD4 CCR6
18 esophageal candidiasis 10.6 CD8A CD4 CCR6
19 mucormycosis 10.6 CLEC7A CD4 CCR6
20 cardiomyopathy, familial hypertrophic, 20 10.6 IL6 CXCL8 CD4
21 t-cell adult acute lymphocytic leukemia 10.6 CD8A CD4 CCR6
22 adult acute lymphocytic leukemia 10.6 CD8A CD4 CCR6
23 autoimmune glomerulonephritis 10.6 CD8A CD4 CCR6
24 ventilation pneumonitis 10.6 CD8A CD4
25 denture stomatitis 10.6 IL6 CXCL8 CLEC7A
26 plasma protein metabolism disease 10.6 IL6 CD4 CCR6
27 epididymis disease 10.6 TLR4 IL6 CD4
28 borst-jadassohn intraepidermal carcinoma 10.6 TLR7 LINC01191 CD8A
29 polyclonal hypergammaglobulinemia 10.6 IL6 CD8A CD4
30 pustulosis of palm and sole 10.6 TNF CXCL8 CCR6
31 chancroid 10.6 CD4 CCR6 CCR5
32 punctate inner choroidopathy 10.6 TNF IL10
33 idiopathic anterior uveitis 10.6 TNF IL6 CXCL8
34 streptococcal toxic-shock syndrome 10.6 TNF IL6 CXCL8
35 acute proliferative glomerulonephritis 10.6 TNF CD4 CCR6
36 mikulicz disease 10.6 IL10 CD4 CCR6
37 t cell deficiency 10.6 CD8A CD4 CCR6
38 necrotizing fasciitis 10.6 IL6 H2AC18 CXCL8
39 immunoglobulin alpha deficiency 10.6 CD8A CD4 CCR6
40 mycobacterium kansasii 10.6 TLR2 CXCL8
41 angelucci's syndrome 10.6 IL1B CXCL8
42 recurrent corneal erosion 10.6 IL6 IL1B CXCL8
43 fungal keratitis 10.6 TLR4 TLR2 CLEC7A
44 diffuse infiltrative lymphocytosis syndrome 10.6 CD8A CD4
45 lung abscess 10.6 TNF IL6 CD4
46 autoimmune lymphoproliferative syndrome, type iia 10.6 CD8A CD4
47 diabetes mellitus, insulin-dependent, 23 10.6 TNF CD8A CD4
48 brachydactyly, type c 10.6 CD8A CD4 CCR6
49 hemorrhagic cystitis 10.6 TLR4 CD8A CD4
50 peptic esophagitis 10.6 IL6 IL1B CXCL8

Graphical network of the top 20 diseases related to Vaginal Disease:



Diseases related to Vaginal Disease

Symptoms & Phenotypes for Vaginal Disease

UMLS symptoms related to Vaginal Disease:


pelvic pain, leukorrhea

MGI Mouse Phenotypes related to Vaginal Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 CCR5 CCR6 CD4 CD8A CLEC7A IL10
2 homeostasis/metabolism MP:0005376 10.16 CCR5 CCR6 CD4 CLEC7A GP5 IL10
3 immune system MP:0005387 10.06 CCR5 CCR6 CD4 CD8A CLEC7A IL10
4 digestive/alimentary MP:0005381 10.02 CCR5 CD4 CLEC7A IL10 IL6 TLR2
5 mortality/aging MP:0010768 9.8 CCR5 CD4 CD8A CLEC7A IL10 IL1B
6 neoplasm MP:0002006 9.23 CCR5 IL10 IL1B IL6 TLR2 TLR3

Drugs & Therapeutics for Vaginal Disease

Drugs for Vaginal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
2
Norethindrone Approved Phase 4 68-22-4 6230
3
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
4
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
5
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
6
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
7
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
8
Desogestrel Approved Phase 4 54024-22-5 40973
9
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
10
Azithromycin Approved Phase 4 83905-01-5 55185 447043
11
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
12
Desflurane Approved Phase 4 57041-67-5 42113
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
15
Polyestradiol phosphate Approved Phase 4 28014-46-2
16
Secnidazole Approved Phase 4 3366-95-8
17
Metronidazole Approved Phase 4 443-48-1 4173
18
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
19
Norethindrone enanthate Experimental Phase 4 3836-23-5
20 Antiviral Agents Phase 4
21 Norethindrone Acetate Phase 4
22 Antioxidants Phase 4
23 Free Radical Scavengers Phase 4
24 N-monoacetylcystine Phase 4
25 Respiratory System Agents Phase 4
26 Antidotes Phase 4
27 Expectorants Phase 4
28 Immunologic Factors Phase 4
29 Immune Sera Phase 4
30 Clindamycin palmitate Phase 4
31 Clindamycin phosphate Phase 4
32 Alkylating Agents Phase 4
33 Central Nervous System Depressants Phase 4
34 Cytochrome P-450 CYP3A Inhibitors Phase 4
35 Cytochrome P-450 Enzyme Inhibitors Phase 4
36 Antifungal Agents Phase 4
37 Steroid Synthesis Inhibitors Phase 4
38 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
39 Contraceptives, Oral Phase 4
40 Contraceptive Agents Phase 4
41 Progestins Phase 4
42 Anesthetics Phase 4
43 Platelet Aggregation Inhibitors Phase 4
44 Anesthetics, General Phase 4
45 Anesthetics, Inhalation Phase 4
46 Estrogens Phase 4
47 Hormone Antagonists Phase 4
48 Hormones Phase 4
49 Estradiol 17 beta-cypionate Phase 4
50 Estradiol 3-benzoate Phase 4

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet for the Treatment of Bacterial Vaginosis Unknown status NCT03080740 Phase 4 Clindamycin palmitate hydrochloride dispersible tablet;Metronidazole Tablet
2 Randomised Control Trial of Probiotics Versus Placebo as Adjuvant to Oral Clindamycin Treatment for Bacterial Vaginosis During Pregnancy Unknown status NCT01558388 Phase 4 Lactobacillus acidophilus;Placebo
3 The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4 Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
4 Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda Unknown status NCT02905890 Phase 4 Norethisterone enantate
5 Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
6 Local, National (Brazil), Multicentric, Open, Non-Controlled, Phase IV, Study of Lactoserum (Dermacyd Femina®), in Women at Reproductive Age, to Prevent Recurrence of Bacterial Vaginosis, During Three Months, After Standard Treatment With Metronidazole. Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
7 A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Metronidazole Vaginal Gel 1.3% in Adolescent Female Subjects With Bacterial Vaginosis Completed NCT02392026 Phase 4 Metronidazole Gel
8 Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis Completed NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
9 Extended Antimicrobial Treatment of Bacterial Vaginosis Combined With Human Lactobacilli to Find the Best Treatment and Minimize the Risk of Relapses Completed NCT01245322 Phase 4 lactobacilli
10 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding Completed NCT00464542 Phase 4 Metronidazole
11 Tinidazole for the Treatment of Bacterial Vaginosis Completed NCT00334633 Phase 4 tinidazole, metronidazole
12 Therapy and Prevention for Sexually Associated Bacterial Vaginosis Completed NCT00324818 Phase 4 metronidazole and azithromycin
13 Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity Completed NCT02445989 Phase 4 NuvaRing
14 Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-controlled Trial Completed NCT01800825 Phase 4 Clindamycin;Placebo
15 Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy Completed NCT00642980 Phase 4 Clindamycin;Placebo;Clindamycin
16 Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4 Desflurane;Sevoflurane
17 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
18 Postmenopausal Pessary Users: Estrogen Versus Trimosan Recruiting NCT03943823 Phase 4 Estrogen vaginal cream;Trimo-San vaginal gel
19 A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis Recruiting NCT03099408 Phase 4 Metronidazole Oral;"Metronidazole" and "Lactobacillus"
20 Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital Recruiting NCT03894813 Phase 4 "Probiotics" and "Metronidazole";Metronidazole Vaginal
21 A Multi-Center, Open-Label Study to Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g Oral Granules for the Treatment of Adolescent Girls With Bacterial Vaginosis Recruiting NCT03937869 Phase 4 Secnidazole
22 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
23 The Use of Colposeptine in Bacterial Vaginosis. A Randomized, Controlled Study Terminated NCT01153958 Phase 4 Colposeptine;Metronidazole
24 Phase III, Randomized, Double Blind, Parallel Groups, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of the Lactobacillus Vaccine Gynevac, in the Treatment of Bacterial Vaginosis Unknown status NCT02173184 Phase 3
25 Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis) Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
26 Phase II Multicentered Randomized Open-label Study of Effectiveness and Safety of Lactofiltrum in Women With Bacterial Vaginosis Unknown status NCT01089348 Phase 2, Phase 3 Lactofiltrum + Metronidazole;Metronidazole
27 Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery Unknown status NCT00491270 Phase 3
28 VA-SENSE - BACTERIAL VAGINOSIS ONCE A WEEK SCREENING AND TREATMENT TO REDUCE INFECTIVE COMPLICATIONS, ABORTION AND PRETERM DELIVERY IN PREGNANT WOMEN WITH PREVIOUS PRETERM DELIVERY. Unknown status NCT01152528 Phase 3
29 The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial Unknown status NCT00536848 Phase 2, Phase 3 Metronidazole
30 A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02418845 Phase 3 SYM-1219;Placebo
31 A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis Completed NCT01621399 Phase 3 Product 55394;Placebo Vehicle (non-treatment)
32 A Phase III Randomized, Multi-center, Double-blind, Double-dummy, Placebo-controlled Treatment Trial of Bacterial Vaginosis With Tinidazole Oral Tablets. Completed NCT00229216 Phase 3 Tinidazole
33 The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis Completed NCT01258556 Phase 2, Phase 3
34 Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310 Completed NCT01586364 Phase 3 Ospemifene 60Mg Oral Tablet
35 Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus: A 40 Week Randomized, Double Blind, Placebo Controlled, Follow-Up to Protocol 15-50310. Completed NCT01585558 Phase 3 Ospemifene (Dose 1);Ospemifene (Dose 2);Placebo
36 A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis Completed NCT03091777 Phase 3 GDC-229;Metronidazole Vaginal Gel 0.75%;Placebo
37 Phase III Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis Completed NCT01125410 Phase 3 Dequalinium chloride;Clindamycin
38 Study of the Efficacy and Safety of Treatment With Total Freeze-dried Culture of Lactobacillus Casei Var. Rhamnosus (Lcr35®) Administered Intravaginally in the Prevention of Bacterial Vaginosis. Randomized, Phase III, Multi-centre, Double-blind, Placebo-controlled Superiority Trial Completed NCT01160796 Phase 3 placebo;Lcr35®
39 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577537 Phase 3 1% SPL7013 Gel;Placebo
40 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577238 Phase 3 1% SPL7013 Gel;Placebo
41 A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
42 Efficacy and Long-Term Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing 60 MG Oral Daily Dose of Ospemifene With Placebo Completed NCT00566982 Phase 3 Ospemifene 60 mg;Placebo
43 Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 30 and 60 Mg Daily Doses With Placebo Completed NCT00276094 Phase 3 Ospemifene 30 mg;Ospemifene 60 mg;Placebo;Nonhormonal vaginal lubricant
44 A Phase 3, Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02452866 Phase 3 SYM-1219
45 Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity, Symptoms of Vulvar and Vaginal Atrophy (VVA), Associated With Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 60 mg Dose With Placebo in Postmenopausal Women Completed NCT00729469 Phase 3 Ospemifene 60 mg;Placebo
46 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis Completed NCT02237950 Phase 3 Metronidazole oral tablets 500mg;1% SPL7013 Gel;Placebo gel
47 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis. Completed NCT02236156 Phase 3 Metronidazole oral tablets 500mg;1% SPL7013 Gel;Placebo gel
48 A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women Completed NCT02210689 Phase 3 clindamycin phosphate vaginal cream 2%
49 A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
50 A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic) Completed NCT01867164 Phase 3 Gynoclin V;Vagitrol V

Search NIH Clinical Center for Vaginal Disease

Cochrane evidence based reviews: vaginal diseases

Genetic Tests for Vaginal Disease

Anatomical Context for Vaginal Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Vaginal Disease:

19
Vagina

MalaCards organs/tissues related to Vaginal Disease:

40
Bone, Testes, Colon, Lung, Liver, Cervix, Eye

Publications for Vaginal Disease

Articles related to Vaginal Disease:

(show top 50) (show all 117)
# Title Authors PMID Year
1
An exploratory pilot study evaluating the supplementation of standard antibiotic therapy with probiotic lactobacilli in south African women with bacterial vaginosis. 42
31533663 2019
2
Low-dose methotrexate-induced vulvar edema: A case report. 42
31464920 2019
3
Vaginismus - who takes interest in it? 42
31324116 2019
4
MRI- and PET-Guided Interstitial Brachytherapy for Postsurgical Vaginal Recurrences of Cervical Cancer: Results of Phase II Study. 61
31682968 2020
5
Association between Vaginal Micro-environment Disorder and Cervical Intraepithelial Neoplasia in a Community Based Population in China. 61
31897224 2020
6
Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors. 61
31718338 2019
7
Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure. 61
31707496 2019
8
Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study. 61
31427275 2019
9
Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease. 61
30650180 2019
10
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. 61
30982556 2019
11
Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: Results of a pilot study. 61
30827725 2019
12
Feasibility of Carbon Ion Radiotherapy in the Treatment of Gynecological Melanoma. 61
30804128 2019
13
Newly Isolated Lactobacilli strains from Algerian Human Vaginal Microbiota: Lactobacillus fermentum Strains Relevant Probiotic's Candidates. 61
29185234 2019
14
Can We Improve Vaginal Tissue Healing Using Customized Devices: 3D Printing and Biomechanical Changes in Vaginal Tissue. 61
30269139 2019
15
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome. 61
30384345 2018
16
Regulation of Herpes Simplex Virus 2 Protein Kinase UL13 by Phosphorylation and Its Role in Viral Pathogenesis. 61
29899106 2018
17
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. 61
28886907 2017
18
Novel ex vivo protocol using porcine vagina to assess drug permeation from mucoadhesive and colloidal pharmaceutical systems. 61
28697437 2017
19
Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. 61
28446260 2017
20
Vulvar and Vaginal Graft versus Host Disease: A Healthcare Clinic Initiative. 61
28503642 2017
21
Clinical analysis of cervical intraepithelial neoplasia with vaginal intraepithelial neoplasia. 61
28445274 2017
22
Role of Molecular Biology in Diagnosis and Characterization of Vulvo-Vaginitis in Clinical Practice. 61
29017160 2017
23
Biotherapeutic agents and vaginal health. 61
26757173 2016
24
Baboon vaginal microbial flora. 61
27198467 2016
25
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. 61
27084683 2016
26
Magnetic resonance imaging of the vagina: an overview for radiologists with emphasis on clinical decision making. 61
26379324 2015
27
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. 61
25693011 2015
28
Clinical characteristics of non-squamous cell carcinoma of the vagina. 61
25594143 2015
29
Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females. 61
25987893 2015
30
Use of a Flexible Inflatable Multi-Channel Applicator for Vaginal Brachytherapy in the Management of Gynecologic Cancer. 61
26442213 2015
31
Spray-dried powders enhance vaginal siRNA delivery by potentially modulating the mucus molecular sieve structure. 61
26347257 2015
32
[Group A streptococcal perineal infection in children]. 61
25456689 2014
33
Botryomycosis of the vulva: a case report. 61
24402357 2014
34
First clinical implementation of the Capri applicator. 61
24423857 2014
35
β-Glucan induces reactive oxygen species production in human neutrophils to improve the killing of Candida albicans and Candida glabrata isolates from vulvovaginal candidiasis. 61
25229476 2014
36
Application of shRNA-containing herpes simplex virus type 1 (HSV-1)-based gene therapy for HSV-2-induced genital herpes. 61
23845900 2013
37
[Laparoscopic radical hysterectomy after initial brachytherapy for stage IB1 cervical cancer: feasibility and results]. 61
24139815 2013
38
Nanopharmaceuticals for improved topical vaginal therapy: can they deliver? 61
23684936 2013
39
Laparoscopic radical hysterectomy after preoperative brachytherapy for stage IB1 cervical cancer: feasibility, results, and surgical implications in a large bicentric study of 162 consecutive cases. 61
22932859 2013
40
Clinical outcomes in international federation of gynecology and obstetrics stage IA endometrial cancer with myometrial invasion treated with or without postoperative vaginal brachytherapy. 61
22365625 2012
41
Subtotal vaginectomy for management of extensive vaginal disease in 11 dogs. 61
22292563 2012
42
Role of vulvar care guidelines in the initial management of vulvar complaints. 61
22227837 2012
43
Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. 61
22318147 2012
44
Effect of quadrivalent HPV vaccination on HPV related disease in women treated for cervical or vulvar/vaginal disease. 61
22454090 2012
45
A caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goats. 61
22511971 2012
46
Vaginal use of Ibuprofen isobutanolammonium (ginenorm): efficacy, tolerability, and pharmacokinetic data: a review of available data. 61
22844609 2012
47
Evaluation of the VITOM in digital high-definition video exocolposcopy. 61
21558961 2011
48
Overlooked diseases of the vagina: a directed anatomic-pathologic approach for imaging assessment. 61
21997983 2011
49
Validation of the ethnopharmacological use of Polygonum persicaria for its antifungal properties. 61
21834226 2011
50
Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review. 61
24592002 2011

Variations for Vaginal Disease

Expression for Vaginal Disease

Search GEO for disease gene expression data for Vaginal Disease.

Pathways for Vaginal Disease

Pathways related to Vaginal Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 TNF TLR9 TLR8 TLR7 TLR4 TLR3
2
Show member pathways
13.73 TNF TLR4 IL6 IL1B IL10 CXCL8
3
Show member pathways
13.4 TNF TLR9 TLR8 TLR7 TLR4 TLR3
4
Show member pathways
13.39 TNF IL6 IL1B IL10 CXCL8 CD4
5
Show member pathways
13.31 TNF TLR9 TLR8 TLR7 TLR4 TLR3
6
Show member pathways
13.23 TNF TLR9 TLR8 TLR7 TLR4 TLR3
7
Show member pathways
13.1 TNF TLR4 TLR3 TLR2 IL6 IL1B
8
Show member pathways
12.97 TNF IL6 IL1B IL10 CXCL8 CD8A
9
Show member pathways
12.97 TNF TLR9 TLR7 TLR4 TLR3 TLR2
10 12.89 TNF TLR9 TLR3 TLR2 IL6 IL1B
11
Show member pathways
12.86 TNF TLR4 TLR3 IL6 IL1B CXCL8
12
Show member pathways
12.85 TNF TLR9 TLR8 TLR7 TLR4 TLR3
13
Show member pathways
12.76 TNF TLR9 TLR8 TLR7 TLR4 TLR3
14
Show member pathways
12.74 TNF TLR4 TLR2 IL6 IL1B IL10
15 12.68 TNF TLR9 TLR8 TLR7 TLR3 TLR2
16
Show member pathways
12.66 TNF IL6 IL1B IL10 CD4
17
Show member pathways
12.61 TNF TLR9 TLR4 TLR2 IL6 IL1B
18
Show member pathways
12.53 TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
19
Show member pathways
12.47 TNF IL6 IL10 CXCL8 CCR6 CCR5
20
Show member pathways
12.45 TNF TLR4 TLR3 IL6 IL1B CXCL8
21
Show member pathways
12.44 TNF TLR2 IL6 IL1B CXCL8
22 12.41 TNF TLR4 IL1B CXCL8
23 12.41 TNF TLR4 IL6 IL1B CXCL8
24
Show member pathways
12.41 TNF TLR4 TLR2 IL1B IL10 CCR5
25
Show member pathways
12.39 TNF TLR9 TLR8 IL6 IL1B IL10
26 12.36 TNF TLR4 IL6 IL1B CXCL8
27
Show member pathways
12.34 TNF IL6 IL1B IL10 CXCL8
28
Show member pathways
12.34 TNF TLR2 IL6 IL1B CXCL8
29
Show member pathways
12.33 TNF TLR4 TLR3 IL1B H2AC18
30 12.33 TNF TLR9 TLR4 TLR2 IL6 IL1B
31 12.29 TNF IL6 IL1B IL10 CXCL8
32 12.28 TNF TLR9 TLR8 TLR7 TLR4 TLR3
33
Show member pathways
12.25 TNF TLR9 TLR8 TLR7 TLR4 TLR3
34 12.2 TNF TLR4 IL6 IL1B IL10 CXCL8
35 12.18 TNF IL6 IL10 GP5 CD8A CD4
36
Show member pathways
12.17 TNF TLR4 TLR2 IL6 IL1B
37
Show member pathways
12.17 TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
38 12.15 TNF TLR4 IL6 IL1B CXCL8
39
Show member pathways
12.13 TNF TLR9 TLR8 TLR7 TLR4 TLR2
40 12.12 TNF IL6 IL1B IL10 CXCL8
41 12.11 TNF IL6 IL1B GP5 CD8A CD4
42
Show member pathways
12.08 IL1B CD8A CD4 CCR5
43 12.07 TNF TLR4 TLR2 IL6 IL1B CXCL8
44 12.05 TNF TLR4 TLR2 IL6 IL1B IL10
45 12.03 TNF TLR4 IL1B CXCL8
46 12.02 TNF IL6 IL1B CXCL8
47 11.98 TNF IL1B IL10 CD8A CD4 CCR6
48 11.94 TNF TLR4 IL6 IL1B IL10 CXCL8
49 11.91 TLR4 IL6 IL1B CXCL8
50 11.91 TLR9 TLR8 TLR7 TLR4 TLR3 TLR2

GO Terms for Vaginal Disease

Cellular components related to Vaginal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 TNF TLR4 TLR3 TLR2 GP5 CD8A
2 cell surface GO:0009986 9.76 TNF TLR4 TLR3 TLR2 CLEC7A CD4
3 endosome membrane GO:0010008 9.72 TLR9 TLR8 TLR7 TLR4 TLR3
4 external side of plasma membrane GO:0009897 9.5 TNF TLR8 TLR4 CD8A CD4 CCR6
5 endolysosome membrane GO:0036020 8.92 TLR9 TLR8 TLR7 TLR3

Biological processes related to Vaginal Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.4 TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.32 TNF TLR9 TLR4 TLR3 TLR2 IL6
3 immune system process GO:0002376 10.26 TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
4 innate immune response GO:0045087 10.23 TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
5 positive regulation of gene expression GO:0010628 10.21 TNF TLR9 TLR4 TLR3 TLR2 IL6
6 negative regulation of cell proliferation GO:0008285 10.16 TLR2 IL6 IL1B IL10 CXCL8
7 cytokine-mediated signaling pathway GO:0019221 10.16 TNF IL6 IL1B IL10 CXCL8 CD4
8 defense response to bacterium GO:0042742 10.14 TNF TLR9 TLR4 TLR3 SLPI IL10
9 cellular response to lipopolysaccharide GO:0071222 10.12 TNF TLR4 IL6 IL1B IL10 CXCL8
10 defense response to virus GO:0051607 10.1 TLR9 TLR8 TLR7 TLR3 IL6
11 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.1 TNF TLR9 TLR4 TLR3 IL1B CD4
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.09 TNF TLR9 TLR4 TLR3 TLR2 IL6
13 response to lipopolysaccharide GO:0032496 10.08 TLR4 TLR2 SLPI IL1B IL10
14 positive regulation of JNK cascade GO:0046330 10.05 TNF TLR9 TLR4 TLR3 IL1B
15 cellular response to mechanical stimulus GO:0071260 10.04 TLR8 TLR7 TLR4 TLR3 IL1B
16 defense response GO:0006952 10.03 TNF TLR3 CXCL8 CCR5
17 positive regulation of DNA-binding transcription factor activity GO:0051091 10.02 TNF IL6 IL1B IL10
18 positive regulation of inflammatory response GO:0050729 10.02 TNF TLR9 TLR7 TLR4 TLR3 TLR2
19 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.01 TNF TLR9 TLR8 TLR7 TLR4 TLR3
20 defense response to Gram-negative bacterium GO:0050829 10 TLR9 TLR4 IL6 CD4
21 toll-like receptor signaling pathway GO:0002224 9.99 TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
22 positive regulation of interleukin-6 secretion GO:2000778 9.98 TNF TLR8 TLR4 TLR2 IL1B
23 positive regulation of tumor necrosis factor production GO:0032760 9.97 TLR9 TLR4 TLR3 TLR2
24 positive regulation of nitric oxide biosynthetic process GO:0045429 9.97 TNF TLR4 IL1B CLEC7A
25 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.97 TLR9 TLR8 TLR7 TLR4 TLR2
26 negative regulation of interleukin-6 production GO:0032715 9.96 TNF TLR9 TLR4 IL10
27 lipopolysaccharide-mediated signaling pathway GO:0031663 9.96 TNF TLR4 TLR2 IL1B
28 microglial cell activation GO:0001774 9.96 TNF TLR8 TLR7 TLR3 TLR2
29 positive regulation of interleukin-12 production GO:0032735 9.95 TLR9 TLR4 TLR3 TLR2
30 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.95 TNF TLR9 TLR7 TLR4 TLR3 TLR2
31 chemokine-mediated signaling pathway GO:0070098 9.94 CXCL8 CCR6 CCR5
32 positive regulation of interferon-beta production GO:0032728 9.94 TLR9 TLR4 TLR3 TLR2
33 response to glucocorticoid GO:0051384 9.93 TNF IL6 IL10
34 apoptotic signaling pathway GO:0097190 9.93 TNF TLR4 TLR3
35 regulation of protein phosphorylation GO:0001932 9.93 TNF TLR8 TLR7
36 positive regulation of T cell proliferation GO:0042102 9.93 IL6 IL1B CD4
37 humoral immune response GO:0006959 9.92 TNF IL6 CCR6
38 T cell activation GO:0042110 9.92 CLEC7A CD8A CD4
39 positive regulation of phagocytosis GO:0050766 9.91 TNF IL1B CLEC7A
40 positive regulation of interferon-gamma production GO:0032729 9.91 TNF TLR4 IL1B
41 positive regulation of JAK-STAT cascade GO:0046427 9.9 TNF IL6 IL10
42 response to molecule of bacterial origin GO:0002237 9.9 TLR9 TLR2 IL10 CXCL8
43 negative regulation of neurogenesis GO:0050768 9.89 TNF IL6 IL1B
44 positive regulation of interferon-gamma biosynthetic process GO:0045078 9.89 TLR9 TLR8 TLR7 TLR3 CLEC7A
45 positive regulation of interleukin-10 production GO:0032733 9.88 TLR9 TLR4 TLR2
46 positive regulation of glial cell proliferation GO:0060252 9.87 TNF IL6 IL1B
47 toll-like receptor 9 signaling pathway GO:0034162 9.87 TLR9 TLR8 TLR7
48 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.87 TNF IL1B IL10
49 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.87 TLR9 TLR4 TLR2
50 positive regulation of interleukin-8 production GO:0032757 9.87 TNF TLR9 TLR7 TLR4 TLR3 TLR2

Molecular functions related to Vaginal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 TNF TLR9 TLR8 TLR7 TLR4 TLR3
2 cytokine activity GO:0005125 9.65 TNF IL6 IL1B IL10 CXCL8
3 signaling receptor activity GO:0038023 9.63 TLR8 TLR4 TLR3 TLR2 CD4 CCR6
4 double-stranded RNA binding GO:0003725 9.61 TLR8 TLR7 TLR3
5 coreceptor activity GO:0015026 9.5 CD8A CD4 CCR5
6 transmembrane signaling receptor activity GO:0004888 9.43 TLR9 TLR8 TLR7 TLR4 TLR3 CD4
7 lipopolysaccharide receptor activity GO:0001875 9.37 TLR4 TLR2
8 signaling pattern recognition receptor activity GO:0008329 9.02 TLR9 TLR8 TLR7 TLR2 CLEC7A

Sources for Vaginal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....